ES2339618T3 - Anticuerpos monoclonales humanizados que protegen contra la enfermedad inducida por la toxina shiga. - Google Patents

Anticuerpos monoclonales humanizados que protegen contra la enfermedad inducida por la toxina shiga. Download PDF

Info

Publication number
ES2339618T3
ES2339618T3 ES98965434T ES98965434T ES2339618T3 ES 2339618 T3 ES2339618 T3 ES 2339618T3 ES 98965434 T ES98965434 T ES 98965434T ES 98965434 T ES98965434 T ES 98965434T ES 2339618 T3 ES2339618 T3 ES 2339618T3
Authority
ES
Spain
Prior art keywords
baselineskip
antibody
humanized monoclonal
binds
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98965434T
Other languages
English (en)
Spanish (es)
Inventor
Jeffrey R. Stinson
Hing Wong
Alison D. O'brien
Clare K. Schmitt
Angela Melton-Celsa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunol Molecular Corp
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Original Assignee
Sunol Molecular Corp
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunol Molecular Corp, Henry M Jackson Foundation for Advancedment of Military Medicine Inc filed Critical Sunol Molecular Corp
Application granted granted Critical
Publication of ES2339618T3 publication Critical patent/ES2339618T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES98965434T 1997-12-23 1998-12-22 Anticuerpos monoclonales humanizados que protegen contra la enfermedad inducida por la toxina shiga. Expired - Lifetime ES2339618T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6863597P 1997-12-23 1997-12-23
US68635P 1997-12-23
US215163 1998-12-18
US09/215,163 US20030170248A1 (en) 1997-12-23 1998-12-18 Humanized monoclonal antibodies that protect against shiga toxin induced disease

Publications (1)

Publication Number Publication Date
ES2339618T3 true ES2339618T3 (es) 2010-05-21

Family

ID=26749187

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98965434T Expired - Lifetime ES2339618T3 (es) 1997-12-23 1998-12-22 Anticuerpos monoclonales humanizados que protegen contra la enfermedad inducida por la toxina shiga.

Country Status (11)

Country Link
US (6) US20030170248A1 (https=)
EP (1) EP1042492B1 (https=)
JP (1) JP4450505B2 (https=)
AT (1) ATE449856T1 (https=)
AU (1) AU764091B2 (https=)
CA (1) CA2316411C (https=)
DE (1) DE69841331D1 (https=)
DK (1) DK1042492T3 (https=)
ES (1) ES2339618T3 (https=)
PT (1) PT1042492E (https=)
WO (1) WO1999032645A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170248A1 (en) * 1997-12-23 2003-09-11 Jeffrey R. Stinson Humanized monoclonal antibodies that protect against shiga toxin induced disease
DK1079856T3 (da) * 1998-05-20 2006-12-04 Teijin Ltd Humaniserede antistoffer til genkendelse af verotoxin II samt cellelinie til produktion af samme
US6858211B1 (en) * 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
CN100523216C (zh) * 2001-03-02 2009-08-05 匹兹堡大学 Pcr方法
US6875433B2 (en) * 2002-08-23 2005-04-05 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
CA2434668A1 (en) 2003-07-04 2005-01-04 Laurence Mulard Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a
CN100441689C (zh) * 2006-01-20 2008-12-10 中国人民解放军第三军医大学 抗ehec o157志贺样毒素ⅱa亚单位单克隆抗体5f3轻、重链可变区基因及应用
EP2420246A1 (en) * 2006-04-20 2012-02-22 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Methods and compositions based on shiga toxin type 1 protein
CA2652999A1 (en) * 2006-05-31 2007-12-13 Thallion Pharmaceuticals Incorporated Methods, compositions, and kits for treating shiga toxin associated conditions
US20090258010A1 (en) * 2006-05-31 2009-10-15 Thallion Pharmaceuticals, Inc. Methods, compositions, and kits for treating shiga toxin associated conditions
EP2172481B1 (en) * 2008-10-06 2014-10-29 Novoplant GmbH Proteolytically stable antibody formats
KR101832499B1 (ko) * 2009-01-23 2018-02-26 더 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신, 인코포레이티드 시가 독소 2형 단백질 기반 방법 및 조성물
RU2732155C1 (ru) * 2019-09-24 2020-09-11 Открытое акционерное общество "Всероссийский научный Центр молекулярной диагностики и лечения" (ОАО ВНЦМДЛ) Гуманизированное антитело или его антигенсвязывающий фрагмент (Fab) против шига-токсинов первого и/или второго типов (варианты), композиция для лечения токсических состояний, вызванных энтерогеморрагической кишечной палочкой, содержащая указанные антитела и/или Fab

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5164298A (en) * 1988-06-24 1992-11-17 Hsc Research Development Corporation Verocytotoxin receptor assay
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
AU669124B2 (en) * 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US5747272A (en) * 1994-02-14 1998-05-05 Henry M. Jackson Foundation For The Advancement Of Military Medicine Detection of shiga-like toxins of enterohemoragic Escherichia coli
US5968894A (en) * 1994-02-22 1999-10-19 Lingwood; Clifford A. Verotoxin pharmaceutical compositions and medical treatments therewith
US7910096B2 (en) * 1996-11-15 2011-03-22 Trustees Of Tufts College Human neutralizing antibodies against hemolytic uremic syndrome
US20020160005A1 (en) * 1996-11-15 2002-10-31 Trustees Of Tufts College Human neutralizing antibodies against hemolytic urmec syndrome
WO1998020903A1 (en) 1996-11-15 1998-05-22 Trustees Of Tufts College Humanized neutralizing antibodies against hemolytic uremic syndrome
US20030170248A1 (en) * 1997-12-23 2003-09-11 Jeffrey R. Stinson Humanized monoclonal antibodies that protect against shiga toxin induced disease
ATE504312T1 (de) * 2003-07-21 2011-04-15 Intervet Int Bv Hybrid-toxine mit shiga-artigen toxin- untereinheiten, verbunden mit escherichia coli wärmeinstabilen enterotoxin-untereinheiten und vakzine daraus
CA2555306A1 (en) * 2004-02-06 2005-08-18 Nymox Corporation Humanized antibody
JP5409014B2 (ja) * 2006-02-16 2014-02-05 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド 志賀トキソイドキメラタンパク質
EP2420246A1 (en) * 2006-04-20 2012-02-22 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Methods and compositions based on shiga toxin type 1 protein
US20090258010A1 (en) * 2006-05-31 2009-10-15 Thallion Pharmaceuticals, Inc. Methods, compositions, and kits for treating shiga toxin associated conditions

Also Published As

Publication number Publication date
CA2316411C (en) 2009-02-17
US20100166753A1 (en) 2010-07-01
PT1042492E (pt) 2010-01-08
US20140135481A1 (en) 2014-05-15
EP1042492A1 (en) 2000-10-11
WO1999032645A1 (en) 1999-07-01
JP4450505B2 (ja) 2010-04-14
EP1042492B1 (en) 2009-11-25
DK1042492T3 (da) 2010-01-18
US20070003560A1 (en) 2007-01-04
JP2003521219A (ja) 2003-07-15
AU2090299A (en) 1999-07-12
AU764091B2 (en) 2003-08-07
ATE449856T1 (de) 2009-12-15
DE69841331D1 (de) 2010-01-07
US20070160607A1 (en) 2007-07-12
US20030170248A1 (en) 2003-09-11
CA2316411A1 (en) 1999-07-01
US20100189715A1 (en) 2010-07-29

Similar Documents

Publication Publication Date Title
US20100166753A1 (en) Humanized monoclonal antibodies that protect against shiga toxin induced disease
ES2363689T3 (es) Anticuerpos monoclonales y quiméricos, opsónicos y protectores, específicos para el ácido lipoteicoico de bacterías gram positivas.
US11447543B2 (en) Antibodies to S. aureus surface determinants
Apter et al. Analysis of the roles of antilipopolysaccharide and anti-cholera toxin immunoglobulin A (IgA) antibodies in protection against Vibrio cholerae and cholera toxin by use of monoclonal IgA antibodies in vivo
Childers et al. Molecular mechanisms of immunoglobulin A defense.
Corthésy Role of secretory immunoglobulin A and secretory component in the protection of mucosal surfaces
ES2366626T3 (es) Anticuerpos contra toxinas de clostridium difficile y usos de los mismos.
AU2013201389B2 (en) Prevention of infection
BR112012026021A2 (pt) anticorpos monoclonais e biespecífico, seus fragmentos de ligação ao antígeno e proteína de ligação para o tratamento de infecção e doença associadas ao clostridium difficile, bem como composição, vacina ou agente imunogênico, linhagem de células de hibridoma, ácido nucleico, processo de produção dos referidos anticorpos, kit, vetor de expressão, método ex vivo e usos
JP2008179634A (ja) グラム陽性細菌のリポタイコ酸に特異的なオプソニン性モノクローナルおよびキメラ抗体
Ahmadi et al. Anti-flagellin IgY antibodies protect against Pseudomonas aeruginosa infection in both acute pneumonia and burn wound murine models in a non-type-specific mode
US20080038262A1 (en) Humanized neutralizing antibodies against hemolytic uremic syndrome
CA2895217C (en) Polyclonal antibodies against clostridium difficile and uses thereof
Kovacs-Nolan et al. Passive immunization through avian egg antibodies
De Greve et al. Single domain antibodies from camelids in the treatment of microbial infections
Neri et al. Specific egg yolk immunoglobulin as a new preventive approach for Shiga-toxin-mediated diseases
US7910096B2 (en) Human neutralizing antibodies against hemolytic uremic syndrome
Li et al. Preparation and characterization of a neutralizing murine monoclonal antibody against tetanus toxin
Jonsson et al. Protective IgM-mediated immunity against Vibrio anguillarum in Atlantic cod with evolutionary losses of mhc class II and cd4
Kociolek et al. Translational aspects of the immunology of Clostridioides difficile infection: implications for pediatric populations
Motley The Role of Anti-Capsular Antibodies in Protection Against Carbapenem-Resistant Klebsiella Pneumoniae
Baranova Adaptation of Vibrio cholerae O1 to Protective, Lipopolysaccharide-Specific Antibodies in the Intestinal Lumen
RU2630663C2 (ru) Антитела для лечения ассоциированных с clostridium difficile инфекции и заболеваний
Ahmed Characterization of the immune response to vibrio cholerae O1 antigens and its impact on vaccine development strategies
Jones et al. Gastrointestinal infections in children